Glutathione: Evidence, Mechanism, Dosing & Legal Status

Glutathione (GSH) is unique among the compounds in this catalog: it is the body's own master intracellular antioxidant — the tripeptide gamma-L-glutamyl-L-cysteinyl-glycine — synthesized in every cell and present at millimolar concentrations.1 Because it is endogenous and sold over the counter, it carries an air of safety that the most heavily marketed route, the intravenous 'drip,' does not deserve. This monograph separates what is proven from what is hyped.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Oral glutathione is a dietary supplement; injectable glutathione for skin lightening is unapproved and has been associated with serious harm and death. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is glutathione and how does it work?

Glutathione is a tripeptide distinguished by an unusual gamma-peptide bond between the side-chain carboxyl of glutamate and the amine of cysteine, rather than the standard alpha-bond. That bond makes it resistant to ordinary intracellular peptidases and degradable only by gamma-glutamyltransferase (GGT), while the reactive cysteinyl thiol (-SH) group is the functional, redox-active center.1 The body makes it in a two-step, ATP-dependent pathway: the rate-limiting enzyme glutamate-cysteine ligase joins glutamate and cysteine, then glutathione synthetase adds glycine. Cysteine availability is the usual limiting input — the rationale behind using N-acetylcysteine (NAC) as an indirect precursor.1

The core mechanism is redox buffering. As a cofactor for glutathione peroxidase (GPx), GSH reduces hydrogen peroxide and lipid peroxides, oxidizing two GSH to one GSSG (glutathione disulfide); glutathione reductase then regenerates GSH using NADPH, and the GSH:GSSG ratio is a core readout of cellular redox state.1 GSH also detoxifies xenobiotics and electrophiles via glutathione-S-transferase conjugation — the 'Phase II detox' basis of its detox marketing — and helps regenerate vitamins C and E. For pigmentation, GSH inhibits tyrosinase (the rate-limiting melanin enzyme) at higher concentrations and chelates copper at its active site; notably it activates tyrosinase below about 3 mM and inhibits it above that, a concentration-dependence relevant to dosing.14 It also shifts pigment synthesis from dark eumelanin toward lighter pheomelanin.15

The hardest question is bioavailability. Standard oral GSH was historically considered poorly absorbed (cited figures around 3 to 5 percent) because the intact tripeptide is largely hydrolyzed in the gut.24 That view has been refined by delivery-system research: liposomal GSH raised whole-blood GSH roughly 40 percent versus about 8 percent for standard powder over 12 weeks, and a 2026 micellar crossover pilot found 2.4 to 4 times greater systemic exposure per dose.34 By contrast, IV glutathione achieves immediate supraphysiologic plasma levels but has a plasma half-life of only about 10 to 15 minutes, so any systemic effect is transient.1

What is the evidence by indication?

Unlike a purely preclinical research peptide, glutathione has real human randomized trials — but they are small, narrow, and uneven across indications. The table summarizes where the evidence actually sits.

The strongest human evidence is for the simplest claim. A 6-month, randomized, double-blind, placebo-controlled trial in 54 non-smoking adults (oral GSH 250 or 1,000 mg/day) showed dose- and time-dependent increases — roughly 30 to 35 percent rises in erythrocyte, plasma and lymphocyte GSH, about 260 percent in buccal cells at the high dose, a fall in the oxidized:reduced ratio, and a more than twofold rise in natural-killer-cell cytotoxicity; levels returned to baseline after a one-month washout.2 A liposomal-GSH trial showed elevations within 1 to 2 weeks.3 The crucial caveat: this proves GSH levels rise, not that any clinical outcome improves.

For skin lightening, human RCTs exist but are small and inconsistent. A 2025 systematic review concluded the overall evidence is mixed, with roughly equal numbers of low- and high-risk-of-bias studies.5 A rigorous multicenter Indonesian double-blind RCT (83 completers; L-glutathione plus vitamin C, alpha-lipoic acid and zinc over 12 weeks) found no statistically significant improvement in skin tone, only a nonsignificant tendency.6 Topical GSH RCTs are more consistent, with 0.5 and 2 percent preparations outperforming placebo on melanin index.7 IV lightening rests on a single placebo-controlled study with a non-significant result (p=0.054), widely criticized for flawed design; an earlier review called IV lightening efficacy essentially unsupported.8 In early NAFLD, an open-label single-arm pilot in 34 patients (300 mg/day for 4 months) showed a significant ALT decrease alongside lower triglycerides and ferritin — promising but uncontrolled, so causation cannot be established.9 For Parkinson's disease, small IV and intranasal RCTs confirmed safety but the active groups did not beat placebo.1113 Readers can track active and completed trials directly at ClinicalTrials.gov.

What doses appear in the literature?

Reported strictly as information, not a protocol. For body stores and general use, oral doses of 250 to 1,000 mg/day appear — the 6-month body-store RCT used 250 or 1,000 mg/day, and liposomal forms at 500 mg/day raised levels within 1 to 2 weeks.23 The NAFLD pilot used 300 mg/day for 4 months.9 Skin-lightening RCTs used 250 mg/day, 250 mg twice daily, or 500 mg/day, often with co-antioxidants, while topical studies used 0.5 and 2 percent preparations.57 IV use (off-label/compounded) is reported at 600 to 1,400 mg per session — the Parkinson's pilot used 1,400 mg three times weekly — and intranasal Parkinson's research used 100 to 600 mg/day in divided doses.1112 The recurring formulation point is that standard oral GSH is extensively gut-degraded, so liposomal, micellar and sublingual routes report higher systemic exposure; sterile compounded injectables, where permitted, must be prepared from injectable-grade material, not dietary-ingredient powder.418

How safe is glutathione?

The safety profile splits sharply by route. Oral glutathione is generally well tolerated across trials, with mild and infrequent GI effects (nausea, bloating, epigastric discomfort); in the Indonesian RCT mild adverse events occurred in about 9 percent of GSH versus 8 percent of placebo, all resolving, and long-term oral safety in the 6-month RCT was favorable.62

Injectable / IV use is the serious concern. Multiple national regulators warn that IV glutathione for skin lightening carries grave risks — Stevens-Johnson syndrome and toxic epidermal necrolysis, hepatic, renal and thyroid dysfunction, severe abdominal pain, air embolism, and bloodborne-infection transmission from non-sterile administration.16 The U.S. FDA found excessive bacterial endotoxin contaminating injectable glutathione samples and warned against compounding sterile injectables from the dietary ingredient.18 At least one death has been reported — a woman with chronic kidney disease who died hours after a glutathione plus stem-cell IV — and reviewers note a narrow margin between purported effective and toxic IV doses.1723 Regulators also flag a theoretical long-term skin-cancer concern from chronic depigmentation and reduced UV-protective eumelanin, and a mechanistic caution that high GSH could protect tumor cells in oncology contexts.17 Co-administration with IV vitamin C in 'drips' raises kidney-stone risk in acidic urine, and inhaled or nebulized GSH can provoke bronchospasm in sulfite-sensitive asthmatics. Caution is warranted in renal or hepatic impairment, and pregnancy and lactation are under-studied — avoid supplemental dosing without clinician guidance.

What is the FDA and WADA status in 2026?

Glutathione is not an FDA-approved finished drug. It is lawfully sold as an oral dietary supplement, with no disease claims permitted, and it is not approved for injection or for skin lightening.18 On compounding, glutathione was nominated for the 503A bulk drug substances list; at the June 8, 2022 Pharmacy Compounding Advisory Committee meeting the committee voted 8-5 (1 abstention) to add it, against FDA staff's recommendation, which cited a lack of effectiveness and safety data.19 Under the FDA's interim policy glutathione sat in the eligible-under-enforcement-discretion category pending a final rule; the FDA's January 7, 2025 guidance ended new nominations going forward while leaving previously categorized substances within interim enforcement scope.20 The practical effect in 2026 is that a 503A pharmacy may compound patient-specific glutathione against a valid prescription but cannot supply office-stock or bulk injectables for general use.21 Internationally, the Philippine FDA and DOH state injectable glutathione is approved only as a cisplatin-chemotherapy adjunct, label skin-whitening use off-label and illegal, and have issued repeated public-danger advisories.1617

For athletes the picture is reassuring on the molecule but not on products. Glutathione is not on the 2026 WADA Prohibited List, in or out of competition, and is not a monitored substance.22 Athletes remain strictly liable, however, so any tested competitor should verify specific products through GlobalDRO and use only batch-tested supplements, since contamination or mislabeling — not the molecule itself — is the real anti-doping hazard.

Bottom line. Glutathione has a legitimate antioxidant identity backed by deep biochemistry and one solid Grade-A human claim — oral dosing raises body stores. But it is oversold for uses its own evidence does not yet support, the real-world bioavailability of oral forms and whether raised levels translate to clinical benefit remain open, and no large definitive RCT exists for any cosmetic or disease indication. The safety verdict is two-tiered: oral GSH is benign, while injectable glutathione for cosmetic use is genuinely dangerous and unapproved. Regulatory facts here are current as of June 2026 and should be re-verified as FDA finalizes its 503A rule.